Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Biologic-Naive Rheumatoid Arthritis (RAMBA)
NCT03652961Phase 4Completed
- Sponsor
- NYU Langone Health
- Start
- Jun 2019
- Primary completion
- Sep 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abatacept in rheumatoid arthritis (RA), sponsored by NYU Langone Health. Primary endpoints: Clinical Disease Activity Index at Month 6 and Disease Activity Score 28-joint count C reactive protein at Month 6. Started Jun 2019; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03652961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652961.